MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) Files An 8-K Financial Statements and Exhibits
Item9.01.
| Financial Statements and Exhibits. |
Financial Statements of Private Miragen
The audited consolidated financial statements of Private Miragen
as of December31, 2016 and 2015, and for each year ended
December31, 2016 and 2015, are filed herewith as Exhibit 99.1 and
are incorporated herein by reference.
Pro Forma Financial Information
The unaudited pro forma condensed combined statements of income
for the year ended December31, 2016, and unaudited pro forma
condensed combined balance sheet as of December31, 2016, each
giving effect to the Merger are filed as Exhibit 99.2 to this
Current Report on Form 8-K and are incorporated herein by
reference.
|
Exhibit No. |
Description |
|
| 99.1 |
Audited consolidated financial statements of Private Miragen as of December 31, 2016 and 2015, and for each year ended December 31, 2016 and 2015. |
|
| 99.2 |
Unaudited pro forma condensed combined statement of income for the year ended December31, 2016, and unaudited pro forma condensed combined balance sheet as of December31, 2016, each giving effect to the Merger. |
2
About MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL)
miRagen Therapeutics Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of micro-ribonucleic acid (RNA)-targeted therapies. Its lead product candidates, MRG-106 and MRG-201, are in Phase I clinical trials. Its therapeutic areas of focus include cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in several blood cancers. The Company’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is developing a pipeline of pre-clinical product candidates. MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) Recent Trading Information
MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) closed its last trading session 00.00 at 12.30 with 38,761 shares trading hands.
